- Meeting abstract
- Open Access
Specific effects of Lef-1 splice variants on the regulation of gene expression in pancreatic cancer cells
© Jesse et al; licensee BioMed Central Ltd. 2009
- Published: 26 February 2009
- Pancreatic Cancer
- Pancreatic Cancer Cell
- Pancreatic Carcinoma
- Human Pancreatic Cancer
- Advanced Tumour Stage
The lymphoid enhancer factor (Lef-1) belongs to the nuclear transducers of canonical Wnt-signalling in embryogenesis and cancer. Lef-1 acts, in cooperation with beta-catenin, as a context-dependent transcriptional activator or repressor thereby influencing multiple cellular functions such as proliferation, differentiation and migration.
Here we report an increased Lef-1 expression in human pancreatic cancer, which correlates with advanced tumour stages. As demonstrated by RT-PCR analysis, pancreatic carcinoma exhibit two different transcripts present in pancreatic carcinomas. One transcript was identified as the full length Lef-1 (Lef-1 FL), whereas the second, shorter transcript, lacked exon VI (Lef-1 exon VI) compared to the published sequence. Comparative analysis of these two Lef-1 variants revealed different cellular effects after transient expression in pancreatic carcinoma cells. Forced expression of Lef-1 exon VI in pancreatic carcinoma cells inhibited E-cadherin expression and resulted in reduced cellular aggregation and increased cell migration compared to cells expressing full length Lef-1. Expression of Lef-1 FL, but not the newly identified Lef-1 exon VI, induced expression of the cell cycle regulating proteins c-myc and cyclin D1 and resulted in enhanced cell proliferation.
Thus, our findings implicate that expression of alternatively spliced isoforms of Lef-1 are involved in the determination of proliferative or migratory characteristics of pancreatic carcinoma cells.
This article is published under license to BioMed Central Ltd.